RxDoctor Payments Data

Aaron Tang, MD

Cardiovascular Disease · Saint Peters, MONPI 1841456522

Payments from drug & device makers

$3,293in general payments, 2019–2025

Across 102 payments — averaging $32.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$707
  • Abbott$453
  • Pfizer$330
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$313
  • Boston Scientific$271
  • Novo Nordisk$256
  • plus $963 from 15 others

What the payments were for

  • Food & beverage$3,293100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,293 in reported general payments places this provider in the 55th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$121,507
Medicare patients
603
Services billed
1,613

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban325$336,669
FarxigaDapagliflozin Propanediol53$49,776
Repatha SureclickEvolocumab53$48,862
JardianceEmpagliflozin39$37,062
EntrestoSacubitril/Valsartan25$34,103
XareltoRivaroxaban18$21,541
BrilintaTicagrelor19$15,323
Praluent PenAlirocumab12$6,321
Metoprolol Succinate177$2,467
Amiodarone Hcl32$2,002
Atorvastatin Calcium209$1,469
Ranolazine ErRanolazine13$1,442
Digoxin25$1,222
Metoprolol Tartrate211$1,032
ClopidogrelClopidogrel Bisulfate77$990

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$330$336,669325 claims
AstraZenecaFarxiga, Brilinta$707$65,10072 claims
NovartisEntresto$193$34,10325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Saint Peters

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →